---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-018403"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:57:53.189874+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ZyVersa enters warrant exercise inducement; expected gross proceeds ~$2.05M

## Summary
- Existing Series A-2 and A-3 warrants with $1 exercise price reduced to $0.67; holder exercises for cash.
- Company issues new Series A-4 warrants to purchase 200% of exercised shares, $0.67 exercise price, 5-year term.
- If all warrants exercised, gross proceeds ~$2.05 million; proceeds for working capital.
- Issuance of inducement warrant shares subject to stockholder approval; registration statement to be filed by August 8, 2025.
- AGP acts as financial advisor, receiving 6.5% cash fee of aggregate gross proceeds.

## SEC filing metadata
- accession: 0001641172-25-018403
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000164117225018403/0001641172-25-018403-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000164117225018403/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-018403
- JSON: https://secwatch.observer/filing/0001641172-25-018403.json
- Plain text: https://secwatch.observer/filing/0001641172-25-018403.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.